Compounded semaglutide is not FDA-approved, is not the same as these brand-name products, and has not been reviewed by the FDA for safety or effectiveness
Expert Opinion on Drug Safety , 18
Typically, tirzepatide is superior for glucose-lowering and for weight loss, reinforces Dr
Beyond their role in weight management, GLP-1R agonists have shown neuroprotective and neurotrophic properties, offering potential benefits in reducing neuroinflammation
Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]
It has just not been scientifically tested, and so thats extremely concerning. Another concern is the quality of compounded weight-loss medicationsthe kind often used for microdosing